ArticleCureus2025
Acute Pancreatitis Associated With Blinatumomab Treatment in a Patient With Acute Lymphoblastic Leukemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blinatumomab, a bispecific T-cell engager, has significantly advanced the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL), with well-established toxicities such as cytokine release syndrome and neurotoxicity. However, pancreatitis remains an exceptionally rare and underrecognized adverse effect, with limited reports outside of clinical trials. This case report presents one of the first documented instances of acute pancreatitis in a patient receiving blinatumomab in a real-world setting, diagnosed by elevated serum lipase and confirmatory CT imaging. The patient's presentation and resolution with supportive care underscore the importance of promptly recognizing and managing this potential complication. Further investigation is warranted to elucidate the pathophysiological mechanisms of this association and to guide clinical decisions regarding blinatumomab safety and rechallenge protocols in affected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.